サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1592653

北米のボツリヌス毒素市場：2031年までの予測 - 地域別分析 - 製品別、用途別、エンドユーザー別

North America Botulinum Toxin Market Forecast to 2031 - Regional Analysis - by Product (Botulinum Toxin A and Botulinum Toxin B), Application (Medical and Aesthetic), and End User (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others)

出版日
ページ情報
英文 77 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
北米のボツリヌス毒素市場：2031年までの予測 - 地域別分析 - 製品別、用途別、エンドユーザー別
出版日: 2024年09月16日
発行: The Insight Partners
ページ情報: 英文 77 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米のボツリヌス毒素市場は、2023年に48億129万米ドルとなり、2031年までには120億7,260万米ドルに達すると予測され、2023年から2031年までのCAGRは12.2%と推定されます。

治療用途の拡大が北米のボツリヌス毒素市場を牽引

A型およびB型ボツリヌス毒素は、神経筋接合部および神経分泌接合部で放出される小胞アセチルコリンをブロックし、神経リハビリテーションの介入を必要とする患者の治療に強力な治療効果をもたらします。臨床報告によると、ボツリヌス毒素は頭痛、唾液分泌、多汗症などに対する治療効果が証明されています。ボツリヌス治療は手術の代替療法として採用することができます。慢性裂肛患者においては、括約筋切開術に代わる有望な治療法であると思われます。プチアリズムや味覚性発汗、腺の分泌過多（患者が耳下腺を含む手術を受けた後にしばしば起こる状態）などの少数の自律神経障害を患っている患者は、ボツリヌス毒素によく反応します。生殖補助医療の分野で多くの進歩があったにもかかわらず、依然としてかなりの数の患者が着床不全を繰り返しています。十分な子宮内膜の成長は、生殖補助医療における胚の着床と妊娠の継続に重要な役割を果たします。数年前から、ボツリヌス毒素は形成外科や美容外科で広く使用されています。ボツリヌス毒素がヒトのケラチノサイトの再上皮化と内皮細胞の血管新生に好影響を与えることが明らかになっています。臨床結果では、ボツリヌス毒素の投与は、細胞増殖と血管形成を増加させ、コラーゲンが蓄積した病変を減少させ、最終的には胚の着床の成功に寄与することによって、損傷した構造と損なわれた子宮内膜の機能の回復を促進することが明らかにされています。このように、ボツリヌス毒素の治療用途の拡大は、今後数年間に新たなボツリヌス毒素市場動向をもたらす可能性が高いです。

北米のボツリヌス毒素市場概要

北米のボツリヌス毒素市場は米国、カナダ、メキシコに区分されます。北米の市場成長は、主に経済的に安定した人口と、上記の国々で行われる非外科的または低侵襲的な美容施術の増加に関連しています。ボツリヌス毒素注射による顔のしわの減少は、米国で最も行われている美容整形です。これは、診療に美容治療を取り入れようとする臨床医にとって、最も一般的なエントリーレベルの治療の一つです。国際美容形成外科学会（ISAPS）によると、2021年には米国で約250万件のボツリヌス毒素施術が行われました。米国食品医薬品局（FDA）により承認された、美容適応の眉間のしわやカラスの足跡、額の横じわの治療は、予測可能な結果をもたらし、副作用が少なく、患者の満足度が高いです。米国で市販されているボツリヌス毒素製剤には、AllerganのBOTOX Cosmetic/Vistabel、GaldermaとIpsenのDysport/Azzalure、MerzのXeomin/Bocouture、EvolusのJeuveau（米国ではDaewoongのみが製造）があります。米国FDAはボトックス化粧品を18歳から65歳までの人々に承認しています。米国美容整形学会によると、ボトックス注射は美容業界で最も急成長している施術です。2023年8月、Daxxify（daxibotulinumtoxinA-lanm）が成人の頸部ジストニアの治療適応として初めてFDAに承認されました。頸部ジストニアは、制御不能な頸部筋肉の痙攣や収縮を特徴とし、異常な動き、ぎこちない姿勢、頭部や頸部の痛みを引き起こします。この疾患は、およそ6万人のアメリカ人が罹患しています。ボツリヌス毒素の注射は、頸部ジストニア患者の患部の筋肉を弛緩させ、硬直や痙攣を軽減します。しかし、治療効果は徐々に失われるため、患者は頻繁に再治療を受ける必要があります。これに先立つ2021年7月、FDAはAbbVie傘下のAllerganのボトックス化粧品の適応拡大を承認しました。Allerganは、成人の上肢痙縮に関連する8つの新たな筋疾患の治療にBOTOXの適応を拡大しました。

北米のボツリヌス毒素市場の収益と2031年までの予測（金額）

北米のボツリヌス毒素市場のセグメンテーション

北米のボツリヌス毒素市場は、製品、用途、エンドユーザー、国に分類されます。

製品別では、北米のボツリヌス毒素市場はボツリヌス毒素Aとボツリヌス毒素Bに二分されます。2023年の北米のボツリヌス毒素市場シェアでは、ボツリヌス毒素Aセグメントが大きなシェアを占めています。

用途別では、北米のボツリヌス毒素市場は医療と美容に二分されます。2023年の北米のボツリヌス毒素市場は、医療セグメントが大きなシェアを占めています。さらに、医療セグメントは慢性片頭痛、筋痙攣、過反応性膀胱、多汗症、その他に細分化されます。さらに、美容セグメントは、しかめ面ライン/グラベラー、額ライン、カラスの足跡、四角い顎/咬筋、その他に細分化されます。

エンドユーザー別では、北米のボツリヌス毒素市場は専門・皮膚科クリニック、病院・クリニック、その他に分けられます。2023年の北米のボツリヌス毒素市場では、専門・皮膚科クリニックセグメントが最大シェアを占めています。

国別では、北米のボツリヌス毒素市場は米国、カナダ、メキシコに区分されます。米国は2023年に北米のボツリヌス毒素市場シェアを独占しました。

Merz Pharma GmbH &Co KGaA、AbbVie Inc、Ipsen SA、Evolus Inc、Aquavit、Revance Therapeutics Inc、Medytox Inc、Galderma SA、Hugel Inc、Lanzhou Institute of Biological Products Co Ltdは、北米のボツリヌス毒素市場で事業を展開する主要企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米のボツリヌス毒素市場：主要市場力学

  • 市場促進要因
    • 非侵襲的美容施術の人気上昇
    • 顔面美容のためのボツリヌス毒素使用の増加
  • 市場抑制要因
    • ボツリヌス毒素の副作用
  • 市場機会
    • 新興国における美容施術の採用増加
  • 今後の動向
    • 治療用途の拡大
  • 促進要因と抑制要因の影響

第5章 ボツリヌス毒素市場：北米分析

  • ボツリヌス毒素市場の売上高、2021年～2031年

第6章 北米のボツリヌス毒素市場の分析：製品別

  • ボツリヌス毒素A
  • ボツリヌス毒素B

第7章 北米のボツリヌス毒素市場の分析：用途別

  • 医療
  • 美容

第8章 北米のボツリヌス毒素市場の分析：エンドユーザー別

  • 専門クリニック・皮膚科クリニック
  • 病院・クリニック
  • その他

第9章 北米のボツリヌス毒素市場：国別分析

  • 北米
    • 米国
    • カナダ
    • メキシコ

第10章 企業プロファイル

  • Merz Pharma GmbH & Co KGaA
  • AbbVie Inc
  • Ipsen SA
  • Evolus Inc
  • Aquavit
  • Revance Therapeutics Inc
  • Medytox Inc
  • Galderma SA
  • Hugel Inc
  • Lanzhou Institute of Biological Products Co Ltd

第11章 付録

図表

List Of Tables

  • Table 1. Botulinum Toxin Market Segmentation
  • Table 2. North America Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 3. North America Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 4. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 5. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 6. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 7. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 8. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 9. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 10. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 11. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 12. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 13. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 14. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 15. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 16. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 17. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 18. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 19. Glossary of Terms

List Of Figures

  • Figure 1. Botulinum Toxin Market Segmentation, by Country
  • Figure 2. Botulinum Toxin Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Botulinum Toxin Market Revenue (US$ Million), 2021-2031
  • Figure 5. Botulinum Toxin Market Share (%) - by Product (2023 and 2031)
  • Figure 6. Botulinum Toxin A: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Botulinum Toxin B: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Botulinum Toxin Market Share (%) - by Application (2023 and 2031)
  • Figure 9. Medical: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Aesthetic: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Botulinum Toxin Market Share (%) - by End User (2023 and 2031)
  • Figure 12. Specialty and Dermatology Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Hospitals and Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. North America: Botulinum Toxin Market, by Key Country - Revenue (2023) (US$ Million)
  • Figure 16. North America: Botulinum Toxin Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 17. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
目次
Product Code: TIPRE00028644

The North America botulinum toxin market was valued at US$ 4,801.29 million in 2023 and is expected to reach US$ 12,072.60 million by 2031; it is estimated to register a CAGR of 12.2% from 2023 to 2031.

Expanding Therapeutic Applications Fuel North America Botulinum Toxin Market

The botulinum toxins type A and B block vesicular acetylcholine released at neuromuscular and neurosecretory junctions, thereby delivering powerful therapeutic outcomes for treating patients requiring neurorehabilitation intervention. As per clinical reports, botulinum toxins have been proven to have therapeutic effects against headache, salivate, and hyperhidrosis, among others. Botulinum treatment can be adopted as an alternative to surgery. It appears to be a promising alternative to sphincterotomy in patients with chronic anal fissures. Patients suffering from a few autonomic disorders such as ptyalism or gustatory sweating, and hypersecretion of glands (a condition that often occurs after patients undergo surgeries involving parotid glands) respond well to botulinum toxins. Despite numerous advancements in the field of assisted reproductive technology, a significant number of patients still suffer from repeated implantation failure. Adequate endometrial growth plays a crucial role in embryo implantation and pregnancy continuation in an assisted reproductive procedure. For several years, botulinum toxins have been widely used in plastic and aesthetic surgeries; it has been revealed that botulinum toxins have a positive influence on the re-epithelialization of human keratinocytes and the angiogenesis of endothelial cells. Clinical results reveal that botulinum toxin administration facilitates the recovery of damaged structure and impaired function of the thin endometrium by increasing cellular proliferation and vessel formation, reducing collagen-accumulated lesions, and ultimately contributing to successful embryo implantation. Thus, the expanding therapeutic applications of botulinum toxins are likely to bring new botulinum toxins market trends in the coming years.

North America Botulinum Toxin Market Overview

The North America botulinum toxin market is segmented into the US, Canada, and Mexico. The market growth in North America can be mainly associated with the economically stable population and increasing numbers of nonsurgical or minimally invasive cosmetic procedures performed in the abovementioned countries. Reduction of facial wrinkles with botulinum toxin injections is the most performed cosmetic procedure in the US. It is one of the most common entry-level procedures for clinicians willing to incorporate aesthetic treatments into their practice. According to the International Society of Aesthetic Plastic Surgery (ISAPS), nearly 2.5 million botulinum toxin procedures were performed in the US in 2021. The treatment of frown lines and crow's feet approved by the US Food and Drug Administration- for cosmetic indications and horizontal forehead wrinkles provide predictable results, have few side effects, and high patient satisfaction. BOTOX Cosmetic/Vistabel by Allergan, Dysport/Azzalure by Galderma and Ipsen, Xeomin/Bocouture by Merz, and Jeuveau by Evolus (manufactured only by Daewoong for the US) are among the commercially available botulinum toxin products in the country. The US FDA has approved BOTOX Cosmetic for people from the age range of 18-65. According to the American Society for Aesthetic Plastic Surgery, botox injection is the fastest-growing procedure in the cosmetic industry. In August 2023, Daxxify (daxibotulinumtoxinA-lanm) was approved by the FDA as the first therapeutic indication to treat adult cervical dystonia. Cervical dystonia is characterized by uncontrollably occurring spasms or contractions in neck muscles, causing unusual movements, awkward posture, and head and neck pain. This condition affects approximately 60,000 Americans. The injection of botulinum toxin facilitates the relaxation of affected muscles in cervical dystonia patients, thereby reducing stiffness and spasms. However, the effect of the treatment slowly wears off, and thus, patients need frequent retreatments. Earlier, in July 2021, the FDA approved the label expansion of BOTOX Cosmetic of Allergan, an AbbVie company. Allergan has expanded BOTOX's applications to treat 8 new muscle conditions related to upper limb spasticity in adults.

North America Botulinum Toxin Market Revenue and Forecast to 2031 (US$ Million)

North America Botulinum Toxin Market Segmentation

The North America botulinum toxin market is categorized into product, application, end user, and country.

Based on product, the North America botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held the larger share of North America botulinum toxin market share in 2023.

In terms of application, the North America botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held the larger share of North America botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow's feet, square jaw/ masseter, and others.

By end user, the North America botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of North America botulinum toxin market in 2023.

Based on country, the North America botulinum toxin market is segmented into the US, Canada, and Mexico. The US dominated the North America botulinum toxin market share in 2023.

Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Aquavit, Revance Therapeutics Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd are some of the leading companies operating in the North America botulinum toxin market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Botulinum Toxin Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
    • 4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
  • 4.2 Market Restraints
    • 4.2.1 Side Effects of Botulinum Toxin
  • 4.3 Market Opportunities
    • 4.3.1 Rising Adoption of Aesthetic Procedure in Emerging Economies
  • 4.4 Future Trends
    • 4.4.1 Expanding Therapeutic Applications
  • 4.5 Impact of Drivers and Restraints:

5. Botulinum Toxin Market - North America Analysis

  • 5.1 Overview
  • 5.2 Botulinum Toxin Market Revenue (US$ Million), 2021-2031

6. North America Botulinum Toxin Market Analysis - by Product

  • 6.1 Overview
  • 6.2 Botulinum Toxin A
    • 6.2.1 Overview
    • 6.2.2 Botulinum Toxin A: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Botulinum Toxin B
    • 6.3.1 Overview
    • 6.3.2 Botulinum Toxin B: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

7. North America Botulinum Toxin Market Analysis - by Application

  • 7.1 Overview
  • 7.2 Medical
    • 7.2.1 Overview
    • 7.2.2 Medical: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
      • 7.2.2.1 North America Botulinum Toxin Market Breakdown, by Medical
  • 7.3 Aesthetic
    • 7.3.1 Overview
    • 7.3.2 Aesthetic: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
      • 7.3.2.1 North America Botulinum Toxin Market Breakdown, by Aesthetic

8. North America Botulinum Toxin Market Analysis - by End User

  • 8.1 Overview
  • 8.2 Specialty and Dermatology Clinics
    • 8.2.1 Overview
    • 8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Hospitals and Clinics
    • 8.3.1 Overview
    • 8.3.2 Hospitals and Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Botulinum Toxin Market - Country Analysis

  • 9.1 North America: Botulinum Toxin Market
    • 9.1.1 North America: Botulinum Toxin Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.1 United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.1.1 Overview
        • 9.1.1.1.2 United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.1.3 United States: Botulinum Toxin Market Breakdown, by Product
        • 9.1.1.1.4 United States: Botulinum Toxin Market Breakdown, by Application
        • 9.1.1.1.4.1 United States: Botulinum Toxin Market Breakdown, by Medical
        • 9.1.1.1.4.2 United States: Botulinum Toxin Market Breakdown, by Aesthetic
        • 9.1.1.1.5 United States: Botulinum Toxin Market Breakdown, by End User
      • 9.1.1.2 Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.2.1 Overview
        • 9.1.1.2.2 Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.2.3 Canada: Botulinum Toxin Market Breakdown, by Product
        • 9.1.1.2.4 Canada: Botulinum Toxin Market Breakdown, by Application
        • 9.1.1.2.4.1 Canada: Botulinum Toxin Market Breakdown, by Medical
        • 9.1.1.2.4.2 Canada: Botulinum Toxin Market Breakdown, by Aesthetic
        • 9.1.1.2.5 Canada: Botulinum Toxin Market Breakdown, by End User
      • 9.1.1.3 Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.3.1 Overview
        • 9.1.1.3.2 Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.3.3 Mexico: Botulinum Toxin Market Breakdown, by Product
        • 9.1.1.3.4 Mexico: Botulinum Toxin Market Breakdown, by Application
        • 9.1.1.3.4.1 Mexico: Botulinum Toxin Market Breakdown, by Medical
        • 9.1.1.3.4.2 Mexico: Botulinum Toxin Market Breakdown, by Aesthetic
        • 9.1.1.3.5 Mexico: Botulinum Toxin Market Breakdown, by End User

10. Company Profiles

  • 10.1 Merz Pharma GmbH & Co KGaA
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 AbbVie Inc
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 Ipsen SA
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Evolus Inc
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Aquavit
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 Revance Therapeutics Inc
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Medytox Inc
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Galderma SA
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments
  • 10.9 Hugel Inc
    • 10.9.1 Key Facts
    • 10.9.2 Business Description
    • 10.9.3 Products and Services
    • 10.9.4 Financial Overview
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Developments
  • 10.10 Lanzhou Institute of Biological Products Co Ltd
    • 10.10.1 Key Facts
    • 10.10.2 Business Description
    • 10.10.3 Products and Services
    • 10.10.4 Financial Overview
    • 10.10.5 SWOT Analysis
    • 10.10.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners